AbCellera Biologics Inc. Common Shares (ABCL) Financials

Key financial figures for AbCellera Biologics Inc. Common Shares (Q3 2026).

AbCellera Biologics Inc. reported revenue of $10.6 million for Q3 FY2026, up 18.8% from the same period a year earlier. The company posted a net loss of $40.8 million, or -$0.13 per share. Operating margin came to -501.13%, against -851.79% a year earlier. Free cash flow for the period was $25.3 million. Across the last 5 reported quarters, quarterly revenue has risen from $9.0 million in Q3 FY2025 to $10.6 million in Q3 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for AbCellera Biologics Inc. are on the SentiSense financials page.

Revenue
$11M
Net Income
-$41M
EPS
$-0.13
Total Assets
$1.5B
Operating Cash Flow
$27M

Recent quarters

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
Q3 FY2026$11M-$41M-$0.13-501.13%$25M
Q2 FY2026$4M-$55M-$0.18-1550.05%-$36M
Q1 FY2026$8M-$43M-$0.14-691.75%-$37M
Q4 FY2025$45M-$9M-$0.03-63.72%-$45M
Q3 FY2025$9M-$57M-$0.19-851.79%-$62M

Recent fiscal years

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
FY2025$75M-$146M-$0.49-288.98%-$174M
FY2024$29M-$163M-$0.55-1091.69%-$187M
FY2023$38M-$146M-$0.51-623.82%-$121M

Frequently asked questions

What was AbCellera Biologics Inc.'s revenue last quarter?

AbCellera Biologics Inc. reported revenue of $10.6 million for Q3 FY2026, up 18.8% from the same period a year earlier.

Is AbCellera Biologics Inc. profitable?

Not in its most recent reported period. AbCellera Biologics Inc. reported a net loss of $40.8 million for Q3 FY2026, a net margin of -383.1% on revenue.

How has AbCellera Biologics Inc.'s margin trended?

Operating margin was -501.13% in Q3 FY2026, compared with -851.79% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.

How much free cash flow did AbCellera Biologics Inc. generate?

AbCellera Biologics Inc. generated free cash flow of $25.3 million in Q3 FY2026, after capital expenditure.

Full income statement, balance sheet and cash flow for AbCellera Biologics Inc. Common Shares on SentiSense, with up to forty quarters and twenty fiscal years of history.